Management Team

BOARD OF DIRECTORS

Scott Pancoast

Since 2005, Mr. Pancoast has served as President and CEO of publicly-traded Lpath Inc., the category leader in bioactive-lipid targeted antibodies. From 1994 to 2004, Mr. Pancoast was managing partner of Western States Investment Corporation, a private San Diego venture capital fund with $30 million to $100 million under management depending on the time period. During that time, he was CEO or interim CEO for six start-up companies and served on the board of directors for over 15 companies, including three public companies. Prior to joining WSIC, he started and ran the Midwest division of a $300 million (in revenues) publicly traded company. He served as the Chairman/President of the San Diego Venture Group during the late 1990s. Mr. Pancoast earned a bachelors degree from the University of Virginia, and an MBA from the Harvard Business School. 

Donald Swortwood

Mr. Swortwood has served as Chairman and CEO of Western States Investment Corporation since its founding in 1977 and has been an active investor in California business for nearly thirty years. His investments have ranged from a business that developed novel technologies for the detection and treatment of gastro-esophageal reflux disease, which was sold to Medtronic; to a leader in SAN network-management-software solutions, which was sold to EMC; to a business that developed the first “ear thermometer,” which was sold to Wyeth. Currently, the Western States portfolio of holdings includes a number of biotech and life science companies. Mr. Swortwood is a graduate of Stanford University. 

Roger Sabbadini, Ph.D.

Dr. Sabbadini, Professor Emeritus at San Diego State University, is the scientific co-founder of Vaxiion and is also the founder of publicly-traded Lpath, Inc., where he currently serves as Vice President and Chief Scientific Officer. He has served as a board member for three for-profit entities and several non-profits.  Dr. Sabbadini is an accomplished scientist, who began his career studying bioactive lipids in the context of heart disease and has expanded that research and expertise into cancer therapeutics and in the prevention of infectious disease. Dr. Sabbadini graduated with a Ph.D. in Physiology from the University of California, Davis. 



EXECUTIVE MANAGEMENT 

Roger Sabbadini, Ph.D., Chief Scientific Officer

Dr. Sabbadini, Professor Emeritus at San Diego State University, is the scientific co-founder of Vaxiion and is also the founder of publicly-traded Lpath, Inc., where he currently serves as Vice President and Chief Scientific Officer. He has served as a board member for three for-profit entities and several non-profits.  Dr. Sabbadini is an accomplished scientist, who began his career studying bioactive lipids in the context of heart disease and has expanded that research and expertise into cancer therapeutics and in the prevention of infectious disease. Dr. Sabbadini graduated with a Ph.D. in Physiology from the University of California, Davis. 



Matthew J. Giacalone, Ph.D., MBA,
  Vice President of Corporate Development and Research

Dr. Giacalone has over 12 years of experience in the area of minicell biology and the use of minicells as delivery vehicles and provides both scientific  and  business development expertise to the company. He manages Vaxiion's robust intellectual property estate and holds several patents and publications  in the minicell-based delivery field. Dr. Giacalone has also served as a business development consultant for a series of start-up biotechnology companies and government organizations and is a graduate of the joint Ph.D./MBA program between San Diego State University and the University of California, San Diego.